Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma

Exclusion Criteria

• •Creatinine \< 2.5 mg/dl;
• •ALT/AST \< 3x normal;
• •Bilirubin \< 2.0 mg/dl;
• •Adequate venous access for apheresis, and no other contraindications for leukapheresis;
• •Take contraceptive measures before recruit to this trial;
• •Written voluntary informed consent is given.
• •Patients with symptoms of central nervous system
• •Accompanied by other malignant tumor
• •Active hepatitis B or C, HIV infection
• •Any other diseases could affect the outcome of this trial
• •Suffering severe cardiovascular or respiratory disease
• •Poorly controlled hypertension
• •A history of mental illness and poorly controlled
• •Taking immunosuppressive agents within 1 week due to organ transplantation or other disease which need long-lasting administration
• •Occurrence of unstable pulmonary embolism, deep vein thrombosis, or other major arterial/venous thromboembolic events 30 days prior to assignment
• •Reaching a steady dose if receiving anticoagulant therapy before assignment
• •Female study participants of reproductive potential must have a negative serum or urine pregnancy test performed within 48 hours before infusion
• •Pregnant or lactating women
• •Subject suffering disease affects the understanding of informed consent or comply with study protocol.